These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36037444)

  • 1. Prebiotics-Controlled Disposable Engineered Bacteria for Intestinal Diseases.
    Fang TT; Zou ZP; Zhou Y; Ye BC
    ACS Synth Biol; 2022 Sep; 11(9):3004-3014. PubMed ID: 36037444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Rewritable Report and Recording of Environmental Stimuli in Engineered Bacterial Populations.
    Zou ZP; Ye BC
    ACS Synth Biol; 2020 Sep; 9(9):2440-2449. PubMed ID: 32794765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice.
    Zou ZP; Du Y; Fang TT; Zhou Y; Ye BC
    Cell Host Microbe; 2023 Feb; 31(2):199-212.e5. PubMed ID: 36758520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprogramming Acetogenic Bacteria with CRISPR-Targeted Base Editing
    Xia PF; Casini I; Schulz S; Klask CM; Angenent LT; Molitor B
    ACS Synth Biol; 2020 Aug; 9(8):2162-2171. PubMed ID: 32610012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
    Ebrahimi V; Hashemi A
    Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplex genome editing of microorganisms using CRISPR-Cas.
    Adiego-Pérez B; Randazzo P; Daran JM; Verwaal R; Roubos JA; Daran-Lapujade P; van der Oost J
    FEMS Microbiol Lett; 2019 Apr; 366(8):. PubMed ID: 31087001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an Efficient Genome Editing Tool in Bacillus licheniformis Using CRISPR-Cas9 Nickase.
    Li K; Cai D; Wang Z; He Z; Chen S
    Appl Environ Microbiol; 2018 Mar; 84(6):. PubMed ID: 29330178
    [No Abstract]   [Full Text] [Related]  

  • 8. CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials.
    Kick L; Kirchner M; Schneider S
    Bioengineered; 2017 May; 8(3):280-286. PubMed ID: 28287876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No apparent p53 activation in CRISPR-engineered gene-edited rabbits.
    Zhang T; Li J; Wang T; Zhao F; Sui T
    J Cell Mol Med; 2021 Nov; 25(21):10313-10317. PubMed ID: 34609046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
    Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
    Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a CRISPR/Cas9 System for Methylococcus capsulatus
    Tapscott T; Guarnieri MT; Henard CA
    Appl Environ Microbiol; 2019 Jun; 85(11):. PubMed ID: 30926729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting targeted genome editing using the hei-tag.
    Thumberger T; Tavhelidse-Suck T; Gutierrez-Triana JA; Cornean A; Medert R; Welz B; Freichel M; Wittbrodt J
    Elife; 2022 Mar; 11():. PubMed ID: 35333175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Portable CRISPR-Cas9
    Goh YJ; Barrangou R
    Appl Environ Microbiol; 2021 Feb; 87(6):. PubMed ID: 33397707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CRISPR-Cas9 System-Mediated Genetic Disruption and Multi-fragment Assembly in
    Shi Y; Zhang L; Zhang M; Chu J; Xia Y; Yang H; Liu L; Chen X
    ACS Synth Biol; 2022 Apr; 11(4):1497-1509. PubMed ID: 35294186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thermostable CRISPR/Cas9 genome editing system and its application in construction of cell factories with thermophilic bacteria: a review].
    LE Y; He X; Sun J
    Sheng Wu Gong Cheng Xue Bao; 2022 Apr; 38(4):1475-1489. PubMed ID: 35470620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
    Liu W; Yang C; Liu Y; Jiang G
    Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPER/Cas in Plant Natural Product Research: Therapeutics as Anticancer and other Drug Candidates and Recent Patents.
    Dey A; Nandy S
    Recent Pat Anticancer Drug Discov; 2021; 16(4):460-468. PubMed ID: 34911411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation protocol for CRISPR/Cas9-mediated CD19 knockout GM24385 cells by flow cytometry and Sanger sequencing.
    Inwood SL; Tian L; Parratt K; Maragh S; Wang L
    Biotechniques; 2022 Jun; 72(6):279-286. PubMed ID: 35703314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
    Tadić V; Josipović G; Zoldoš V; Vojta A
    Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.